ReviewCancer prevention research (Philadelphia, Pa.)2020
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.
Review in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16.Analytical and bioanalytical chemistry · 2026Article
- Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation.Experimental hematology & oncology · 2026Article
- Enhancing the positive predictive value of early-stage ovarian cancer detection using a two-step machine learning framework.Journal of translational medicine · 2026Article
- Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.Cancers · 2026Review
- IgG Gal-ratio, a promising serum biomarker for detecting ovarian cancer in as early as stage I disease.Journal of ovarian research · 2026Article
- Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.Journal of ovarian research · 2025Article
- Knowledge, attitudes, and barriers regarding health promotion of ovarian cancer among community pharmacists in Jordan.Future science OA · 2025Article
- Curcumin's Therapeutic Potential in Ovarian Cancer: Current Insights and Future Perspectives.Food science & nutrition · 2025Review
- Advances in biomonitoring technologies for women's health.Nature communications · 2025Review
- Big data analysis reveals miR-874 as a suppressor and therapeutic target in the progression from endometriosis to ovarian cancer.Discover oncology · 2025Article
- Expression profiling of KRAS and NOXA genes as prospective biomarkers in ovarian carcinoma.Scientific reports · 2025Article
- Explainable Machine Learning for the Early Clinical Detection of Ovarian Cancer Using Contrastive Explanations.Journal of clinical medicine · 2025Article
- Decoding the Link Between Talcum Powder and Ovarian Cancer: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.ACS nano · 2025Review
- Global, regional, and national burden of ovarian cancer in women aged 45 + from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study.Journal of cancer research and clinical oncology · 2025Article
- Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection.iScience · 2025Article
- Bisphenol A in the Urine: Association with Urinary Creatinine, Impaired Kidney Function, Use of Plastic Food and Beverage Storage Products but Not with Serum Anti-Müllerian Hormone in Ovarian Malignancies.International journal of molecular sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
More than two-thirds of all women diagnosed with epithelial ovarian cancer (EOC) will die from the disease (>14,000 deaths annually), a fact that has not changed considerably in the last three decades. Although the 5-year survival rates for most other solid tumors have improved steadily, ovarian cancer remains an exception, making it the deadliest of all gynecologic cancers and five times deadlier than breast cancer. When diagnosed early, treatment is more effective, with a 5-year survival rate of up to 90%. Unfortunately, most cases are not detected until after the cancer has spread, resulting in a dismal 5-year survival rate of less than 30%. Current screening methods for ovarian cancer typically use a combination of a pelvic examination, transvaginal ultrasonography, and serum cancer antigen 125 (CA125), but these have made minimal impact on improving mortality. Thus, there is a compelling unmet need to develop new molecular tools that can be used to diagnose early-stage EOC and/or assist in the clinical management of the disease after a diagnosis, given that more than 220,000 women are living with ovarian cancer in the United States and are at risk of recurrence. Here, we discuss the state of advancing liquid-based approaches for improving the early detection of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.